Rheumatic Fever

Comprehensive Clinical Guide: Rheumatic Fever (Acute Rheumatic Fever)

1. Introduction and Clinical Overview

Acute Rheumatic Fever (ARF) is a systemic, nonsuppurative inflammatory disease that occurs as a delayed, exaggerated immune response to an infection with Group A Streptococcus (GAS) pyogenes (specifically pharyngitis). While the initial streptococcal infection is localized to the pharynx, ARF represents a multi-system autoimmune sequela that can affect the heart, joints, central nervous system, subcutaneous tissues, and skin.

Despite being largely preventable through the timely administration of antibiotics for streptococcal pharyngitis, ARF remains a leading cause of acquired heart disease in children and young adults globally, particularly in developing nations and low-socioeconomic settings. The most critical morbidity associated with ARF is Rheumatic Heart Disease (RHD), characterized by chronic valvular damage resulting from repeated or severe episodes of rheumatic carditis.

2. Etiology and Pathophysiology: The Molecular Mimicry Mechanism

The pathogenesis of ARF is rooted in the concept of molecular mimicry. The immune system, in its attempt to clear the Streptococcus pyogenes infection, produces antibodies and T-cells that cross-react with host tissues.

The Mechanism of Action:

1. Antigenic Similarity: The M protein of the Group A Streptococcus shares structural homology with human proteins found in the heart (myosin), joints, and brain (basal ganglia).
2. Autoimmune Cascade: Following an untreated or inadequately treated pharyngeal infection (usually 2–4 weeks prior), the host’s immune system mistakenly attacks its own connective tissues.
3. Inflammatory Response: This leads to the formation of Aschoff bodies—pathognomonic microscopic granulomatous lesions found in the heart, characterized by central fibrinoid necrosis surrounded by inflammatory cells (Anitschkow cells/caterpillar cells).

3. Clinical Staging, Presentation, and Diagnosis

The diagnosis of ARF is guided by the Jones Criteria, which were recently revised by the American Heart Association (AHA) to account for varying risk populations.

The Revised Jones Criteria

A diagnosis of ARF requires evidence of a preceding GAS infection plus two major criteria OR one major and two minor criteria.

Major Criteria:
* Carditis: Manifesting as a new murmur (mitral or aortic regurgitation), pericarditis, or evidence of congestive heart failure.
* Polyarthritis: Migratory arthritis affecting large joints.
* Chorea (Sydenham Chorea): Involuntary, purposeless movements, emotional lability, and muscle weakness.
* Erythema Marginatum: A painless, evanescent, pink, ring-like rash on the trunk or proximal extremities.
* Subcutaneous Nodules: Painless, firm, mobile nodules over bony prominences.

Minor Criteria:
* Polyarthralgia (pain without objective inflammation).
* Fever (≥38.5°C).
* Elevated acute phase reactants (ESR, CRP).
* Prolonged PR interval on ECG.

4. Differential Diagnosis

Because ARF mimics several other inflammatory conditions, clinicians must perform a rigorous exclusion process:

1. Juvenile Idiopathic Arthritis (JIA): Typically lacks the migratory nature of rheumatic arthritis and the clear association with a preceding sore throat.
2. Post-Streptococcal Reactive Arthritis (PSRA): Occurs closer to the infection and does not typically involve the heart.
3. Infective Endocarditis: Must be ruled out if a new murmur is present; usually presents with high-grade bacteremia and embolic phenomena.
4. Systemic Lupus Erythematosus (SLE): Often presents with more systemic involvement (renal, hematologic) and specific autoantibodies (ANA, anti-dsDNA).
5. Viral Myocarditis: Can present with similar cardiac symptoms but lacks the specific streptococcal evidence.

5. Diagnostic Testing Protocols

To confirm ARF, a multi-modal approach is required:

• Microbiological Evidence: Throat culture (often negative by the time ARF symptoms appear) or Rapid Antigen Detection Test (RADT). Serological testing (Anti-Streptolysin O [ASO] titer or Anti-DNase B) is more reliable for confirming recent infection.
• Cardiac Imaging: Echocardiography is mandatory in all suspected cases to identify subclinical carditis (valvular regurgitation/stenosis).
• Inflammatory Markers: ESR and CRP are essential to monitor the inflammatory status.
• Electrocardiogram (ECG): To screen for conduction abnormalities, particularly a prolonged PR interval (first-degree AV block).

6. Treatment and Management

Treatment focuses on three pillars: eradicating the streptococcal infection, managing inflammation, and secondary prophylaxis.

Pharmacological Interventions

1. Antibiotics: A full course of Benzathine Penicillin G (or oral Penicillin V/Amoxicillin) is required to eliminate any residual streptococci, even if cultures are negative.
2. Anti-inflammatory Therapy:
   • Salicylates (Aspirin): The gold standard for arthritis and mild carditis.
   • Corticosteroids (Prednisone): Reserved for patients with severe carditis and evidence of heart failure.
3. Heart Failure Management: Diuretics, ACE inhibitors, and beta-blockers as indicated by clinical status.

Secondary Prophylaxis

The most vital aspect of long-term care is the prevention of recurrent GAS infections to avoid cumulative cardiac damage.
* Duration: Depends on the severity of the initial carditis. Patients with residual heart disease may require prophylaxis into their 40s or for life.
* Agent of Choice: Intramuscular Benzathine Penicillin G every 3–4 weeks.

7. Risks, Contraindications, and Long-Term Prognosis

• Risks: The primary risk is the progression to chronic RHD, characterized by permanent valvular scarring, atrial fibrillation, and potential stroke or heart failure.
• Contraindications: Avoid non-steroidal anti-inflammatory drugs (NSAIDs) other than aspirin in the acute phase, as they may mask the clinical course of the disease.
• Prognosis: The prognosis is excellent if the diagnosis is made early and secondary prophylaxis is strictly adhered to. However, once RHD is established, the condition is irreversible and may require surgical valve replacement.

8. Massive FAQ Section

Q1: Is Rheumatic Fever contagious?
No. Rheumatic fever itself is not contagious. However, the preceding streptococcal infection is highly contagious via respiratory droplets.

Q2: Can Rheumatic Fever be prevented?
Yes. The most effective prevention is the prompt and complete treatment of streptococcal pharyngitis (strep throat) with a full course of antibiotics.

Q3: Why is an echocardiogram necessary?
Echocardiograms can detect "subclinical carditis"—inflammation of the heart valves that is not yet audible through a stethoscope. Detecting this early is vital for determining the duration of prophylaxis.

Q4: What is the significance of the "caterpillar" cell?
The Anitschkow cell (caterpillar cell) is a histopathological hallmark of the Aschoff body, indicating the specific inflammatory process of rheumatic heart disease.

Q5: How long do I need to take penicillin injections?
It varies. If you had carditis, you may need them for 10 years or until age 40. If you did not have carditis, 5 years or until age 21 is the standard recommendation.

Q6: What is Sydenham Chorea?
It is a neurological manifestation of ARF, often referred to as "St. Vitus' Dance." It involves involuntary, jerky movements of the face and limbs and often resolves spontaneously, though it can persist for months.

Q7: Can adults get Rheumatic Fever?
While most common in children aged 5–15, it can occur in adults, though it is significantly less frequent.

Q8: What are the common symptoms of a strep throat that might lead to ARF?
Sudden sore throat, fever, tonsillar exudates, and tender cervical lymphadenopathy. Notably, cough and rhinorrhea are usually absent.

Q9: Does having had Rheumatic Fever increase my risk for other heart issues?
Yes. It significantly increases the risk of developing chronic valvular disease, which can lead to infective endocarditis later in life.

Q10: Is there a vaccine for Rheumatic Fever?
Currently, there is no commercially available vaccine for Group A Streptococcus. Research is ongoing, but primary prevention remains reliant on antibiotic therapy.

9. Clinical Summary Table: Management Strategy

Disclaimer: This guide is intended for educational and clinical reference purposes for healthcare professionals. It does not replace clinical judgment or institutional protocols. Always consult current AHA guidelines and local infectious disease policies.